---
layout: default
title: Acer Nigrum Whole Aesculus Hippocastanum Flower Al
parent: 僅模型預測 (L5)
nav_order: 73
evidence_level: L5
indication_count: 0
---

# Acer Nigrum Whole Aesculus Hippocastanum Flower Al
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Botanical Formula: Insufficient Evidence for Repurposing Evaluation

## One-Sentence Summary

This candidate consists of a 28-ingredient botanical/homeopathic combination (including Arnica Montana, American Ginseng, Aloe Vera, Capsicum, and other plant-derived materials), with no established original indication on record.
The TxGNN model **did not generate any predicted indications** for this formula, and no clinical trials, literature evidence, or regulatory approvals were identified.
At this stage, there is **no actionable evidence** to support a repurposing evaluation.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | None on record |
| Predicted New Indication | None (TxGNN returned no predictions) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction only; in this case, no prediction was generated |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

The subject of this evaluation is not a single chemical entity but rather a **28-component botanical mixture**, whose ingredients include:

- Flower extracts: *Aesculus hippocastanum*, *Arnica montana*, *Borago officinalis*, *Nelumbo nucifera*, *Olea europaea*, *Prunella vulgaris*, *Prunus persica*, *Syringa vulgaris*, *Tropaeolum majus*, *Verbena officinalis*, *Zinnia elegans*, *Carpinus betulus*, *Cornus nuttallii*, *Fuchsia magellanica*, *Iris missouriensis*, *Rudbeckia hirta*
- Whole-plant materials: *Acer nigrum*, *Anagallis arvensis*, *Alfalfa*, *Umbellularia californica*
- Functional ingredients: Aloe Vera, American Ginseng, Capsicum, Chaste Tree, Phosphoric Acid
- Alkaloid-containing botanicals: *Strychnos nux-vomica* seed (strychnine source), *Ulmus procera*
- Homeopathic salts: Quinine arsenite

TxGNN is trained to generate repurposing predictions for **single active pharmaceutical ingredients (APIs)** with known DrugBank identifiers. This formula has no DrugBank ID, no unified pharmacological mechanism, and no mapped disease nodes in the knowledge graph. As a result, the model pipeline could not produce a valid prediction output.

Additionally, complex multi-ingredient botanical or homeopathic mixtures present a fundamental challenge for AI-driven repurposing: their pharmacological activity cannot be reliably reduced to a single mechanism-of-action node in the TxGNN knowledge graph.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note on specific ingredients**: Although no formal safety data was retrieved through the DDI pipeline, this formula contains ingredients that warrant attention:
> - **Strychnos nux-vomica seed** contains strychnine, a potent alkaloid with a narrow therapeutic index.
> - **Quinine arsenite** contains arsenic; chronic arsenic exposure carries well-documented toxicological risks.
> - **Capsicum** (capsaicin) may cause mucosal irritation at higher concentrations.
>
> Any clinical use evaluation should assess each ingredient individually for safety signals.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN model requires a single, well-characterized API with a DrugBank ID to generate repurposing predictions. This 28-ingredient botanical/homeopathic formula does not meet that prerequisite, resulting in zero predictions, zero clinical evidence, and zero regulatory approvals in any queried jurisdiction.

**To proceed, the following is needed:**

- **Clarify the active ingredient**: Identify which of the 28 components is the intended focus for repurposing evaluation (e.g., if Capsicum/capsaicin or American Ginseng/ginsenoside is the primary agent, submit it as a standalone candidate).
- **Resolve product identity**: Obtain a DrugBank ID or equivalent structured identifier to enable TxGNN knowledge-graph mapping.
- **Verify intended indication**: Determine whether this formula has any historical use or clinical rationale that could guide a targeted evidence search.
- **Conduct ingredient-level safety review**: Each of the 28 components — particularly *Strychnos nux-vomica* and Quinine arsenite — should be individually assessed for safety before any further evaluation proceeds.
- **Reassess pipeline eligibility**: If this is a homeopathic product with no established pharmacological mechanism, it may fall outside the scope of AI-driven drug repurposing tools entirely.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

